
September 25–27, 2025
Cambridge, MA
Day(s)
:
Hour(s)
:
Minute(s)
:
Second(s)
The CMT Research Foundation unites the voices of patients, researchers, pharma companies, investors and regulatory agencies to develop treatments for CMT.
This event takes place over three days. Thursday and Friday are scientific meetings tailored toward investors, researchers and scientists working to better understand, and ultimately, end CMT. Saturday is primarily for patients and their families, providing a chance to interact with and inform the research community that is working so hard on their behalf. Attendees will have the opportunity to engage with others in the patient community, better understand their disease, and learn how they can participate in the latest research progress.
For the Scientific Community
September 25-26th
Two days for researchers, industry and government agencies to:
- EXPLORE cutting-edge and emerging research in CMT
- ADDRESS major barriers and opportunities in CMT drug development to accelerate progress
- ENGAGE with researchers, industry experts and patients to build momentum toward developing approved CMT treatments
For the Patient Community
September 27th
A day for the patient community to:
- LEARN about the latest developments and clinical trials in CMT
- INTERACT with distinguished scientific experts and clinicians
- ACT to speed treatments for patients and families
Keynote Speaker
Scientific Programming: Dr. Mary Reilly
Professor of Neurology
University College London, Department of Neuromuscular Diseases
Dr. Mary Reilly will be discussing the significant progress in CMT translational research and considerations for effectively advancing CMT therapeutics.
The Royal Sonesta Boston
40 Edwin H Land Blvd
Cambridge, MA 02142
Discounted hotel rates are available for Convention attendees. To reserve your room within our group block, click here.
Thank you to our 2025 Sponsors!
If you are interested in securing a sponsorship opportunity, please contact Anna Combes at [email protected].
The Scientific Programming Committee
Afrooz Rashnonejad, MSc, PhD, Co-Chair
Principal Investigator, Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children’s Hospital
Assistant Professor, Department of Pediatrics, The Ohio State University College of Medicine
Brett McCray, MD, PhD, Co-Chair
Assistant Professor of Neurology
University of Michigan
Charles Abrams, MD, PhD
Professor of Neurology and Rehabilitation
University of Illinois, Chicago
Stephan Zuchner, MD, PhD, FANN
Professor of Human Genetics and Neurology
University of Miami Miller School of Medicine
Rob Burgess, PhD
Professor
The Jackson Laboratory